ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

European Cystic Fibrosis Society   295  OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS INTERACTIONS IN PATIENTS ON CFTR MODULATORS CHAPTER 17 can be associated with a decline in clinical condition and lung function. Therefore, hemoptysis management needs to be care- fully balanced with the other clinical priori- ties of the patient. Modifying treatments on review and considering alternative options where available, can help to ensure that patient care is optimally managed.